Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more
Cosmo Pharmaceuticals N.V - Asset Resilience Ratio
Cosmo Pharmaceuticals N.V (CMOPF) has an Asset Resilience Ratio of 0.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Cosmo Pharmaceuticals N.V's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cosmo Pharmaceuticals N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.18 Million | 0.19% |
| Total Liquid Assets | $1.18 Million | 0.19% |
Asset Resilience Insights
- Limited Liquidity: Cosmo Pharmaceuticals N.V maintains only 0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cosmo Pharmaceuticals N.V Industry Peers by Asset Resilience Ratio
Compare Cosmo Pharmaceuticals N.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198 |
Drug Manufacturers - General | 0.00% |
|
PharmGen Science Inc
KO:004720 |
Drug Manufacturers - General | 0.16% |
Annual Asset Resilience Ratio for Cosmo Pharmaceuticals N.V (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Cosmo Pharmaceuticals N.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.26% | $98.67 Million | $646.77 Million | +15.62pp |
| 2023-12-31 | -0.37% | $-2.04 Million | $553.98 Million | -7.63pp |
| 2022-12-31 | 7.26% | $55.13 Million | $759.59 Million | +4.32pp |
| 2021-12-31 | 2.94% | $23.65 Million | $805.56 Million | -1.58pp |
| 2020-12-31 | 4.51% | $26.91 Million | $596.16 Million | -22.46pp |
| 2019-12-31 | 26.97% | $157.82 Million | $585.16 Million | +4.80pp |
| 2018-12-31 | 22.18% | $138.75 Million | $625.69 Million | +16.60pp |
| 2017-12-31 | 5.57% | $27.76 Million | $497.97 Million | -5.44pp |
| 2016-12-31 | 11.01% | $48.84 Million | $443.47 Million | +0.72pp |
| 2015-12-31 | 10.29% | $45.06 Million | $437.94 Million | -0.94pp |
| 2014-12-31 | 11.23% | $25.33 Million | $225.62 Million | -38.91pp |
| 2013-12-31 | 50.13% | $121.82 Million | $243.00 Million | +50.13pp |
| 2012-12-31 | 0.00% | $1.00 | $151.84 Million | -0.11pp |
| 2010-12-31 | 0.11% | $101.00K | $91.83 Million | -0.08pp |
| 2009-12-31 | 0.19% | $139.00K | $71.46 Million | -- |